IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025

Aggregated presentation by day and by market



Statement of transactions in own shares from August 25th to August 29th 2025

Name of the issuerIdentity code of the issuer

(Legal Entity Identifier) 		Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)
IPSEN549300M6SGDPB4Z94P1125/08/2025FR0010259150 300116,2AQEU
IPSEN549300M6SGDPB4Z94P1125/08/2025FR0010259150 602116,36478CCXE
IPSEN549300M6SGDPB4Z94P1125/08/2025FR0010259150 300116,16733TQEX
IPSEN549300M6SGDPB4Z94P1125/08/2025FR0010259150 3 134116,40348XPAR
IPSEN549300M6SGDPB4Z94P1126/08/2025FR0010259150 300114,5AQEU
IPSEN549300M6SGDPB4Z94P1126/08/2025FR0010259150 600115,2CCXE
IPSEN549300M6SGDPB4Z94P1126/08/2025FR0010259150 300116,1TQEX
IPSEN549300M6SGDPB4Z94P1126/08/2025FR0010259150 3 077115,57995XPAR
IPSEN549300M6SGDPB4Z94P1127/08/2025FR0010259150 300116,9AQEU
IPSEN549300M6SGDPB4Z94P1127/08/2025FR0010259150 113116,8CCXE
IPSEN549300M6SGDPB4Z94P1127/08/2025FR0010259150 3 400117,35488XPAR
IPSEN549300M6SGDPB4Z94P1128/08/2025FR0010259150 600117,9CCXE
IPSEN549300M6SGDPB4Z94P1128/08/2025FR0010259150 3 400117,82XPAR
IPSEN549300M6SGDPB4Z94P1129/08/2025FR0010259150 300116,4AQEU
IPSEN549300M6SGDPB4Z94P1129/08/2025FR0010259150 800116,7625CCXE
IPSEN549300M6SGDPB4Z94P1129/08/2025FR0010259150 200116,4TQEX
IPSEN549300M6SGDPB4Z94P1129/08/2025FR0010259150 3 228117,06431XPAR
   TOTAL20 954 116,7608 

Attachment



EN
02/09/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

Emmanuel Matot ... (+2)
  • Emmanuel Matot
  • Stephane Houri
DHL DHL GROUP
AKE ARKEMA
INFINEON INFINEON TECHNOLOGIES AG
LUFTHANSA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
FP TOTAL SE
VIE VEOLIA ENVIRONNEMENT SA
EDEN EDENRED SA
IPN IPSEN SA
EQNR EQUINOR ASA
SESGL SES SA FDR (CLASS A)
SREN SWISS RE AG
GALP GALP ENERGIA SGPS SA CLASS B
ENI ENI S.P.A.
01913 PRADA S.P.A.
REP REPSOL SA
SOI SOITEC SA
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
OTP OTP BANK NYRT
MELE MELEXIS NV
TIT TELECOM ITALIA S.P.A.
PRY PRYSMIAN S.P.A.
SPIE SPIE SA
FNTN FREENET AG
IDR INDRA SISTEMAS S.A. CLASS A
BP. BP P.L.C.
REY REPLY S.P.A.
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
SIGN SIG COMBIBLOC GROUP LTD
WAVE WAVESTONE SA
AG1 AUTO1 GROUP
NA9 NAGARRO
UMG UNIVERSAL MUSIC GROUP NV
DSY DASSAULT SYSTEMES SA
OVH OVH GROUPE
SHEL SHELL PLC
ARM ARM HOLDINGS PLC
EXENS EXOSENS
ALHG LOUIS HACHETTE GROUP
1h / 43m 1h / 43m 1 EN
Emmanuel Matot ... (+2)
  • Emmanuel Matot
  • Stephane Houri
DHL DHL GROUP
AKE ARKEMA
INFINEON INFINEON TECHNOLOGIES AG
LUFTHANSA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
FP TOTAL SE
VIE VEOLIA ENVIRONNEMENT SA
EDEN EDENRED SA
IPN IPSEN SA
EQNR EQUINOR ASA
SESGL SES SA FDR (CLASS A)
SREN SWISS RE AG
GALP GALP ENERGIA SGPS SA CLASS B
ENI ENI S.P.A.
01913 PRADA S.P.A.
REP REPSOL SA
SOI SOITEC SA
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
OTP OTP BANK NYRT
MELE MELEXIS NV
TIT TELECOM ITALIA S.P.A.
PRY PRYSMIAN S.P.A.
SPIE SPIE SA
FNTN FREENET AG
IDR INDRA SISTEMAS S.A. CLASS A
BP. BP P.L.C.
REY REPLY S.P.A.
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
SIGN SIG COMBIBLOC GROUP LTD
WAVE WAVESTONE SA
AG1 AUTO1 GROUP
NA9 NAGARRO
UMG UNIVERSAL MUSIC GROUP NV
DSY DASSAULT SYSTEMES SA
OVH OVH GROUPE
SHEL SHELL PLC
ARM ARM HOLDINGS PLC
EXENS EXOSENS
ALHG LOUIS HACHETTE GROUP
1h / 54m 1h / 54m 1 FR
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
2h / 33m 2h / 33m 1 EN
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
3h / 51m 3h / 51m 1 FR
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

February 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch